166 related articles for article (PubMed ID: 11297977)
1. Health, trade, and industry officials set to debate access to essential drugs.
Kapp C
Lancet; 2001 Apr; 357(9262):1105. PubMed ID: 11297977
[No Abstract] [Full Text] [Related]
2. GSK: please extend patent pool to AIDS drugs.
Douste-Blazy P; Bermudez J
Lancet; 2009 Apr; 373(9672):1339. PubMed ID: 19376450
[No Abstract] [Full Text] [Related]
3. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
4. Facilitating access of AIDS drugs while maintaining strong patent protection.
Ziker D
Duke Law Technol Rev; 2001 Dec; ():E1. PubMed ID: 15709282
[TBL] [Abstract][Full Text] [Related]
5. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
6. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
7. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
8. Should Third-World countries pay the tab for new drug development?
Gurwitz D
Acad Med; 1999 Mar; 74(3):203. PubMed ID: 10099632
[No Abstract] [Full Text] [Related]
9. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
10. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
11. Debate on essential medicines heats up.
Kapp C
Lancet Infect Dis; 2001 Nov; 1(4):215. PubMed ID: 11871503
[No Abstract] [Full Text] [Related]
12. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
13. Do patents prevent access to drugs for HIV in developing countries?
Selgelid MJ; Schuklenk U
JAMA; 2002 Feb; 287(7):842-3. PubMed ID: 11851570
[No Abstract] [Full Text] [Related]
14. Do patents prevent access to drugs for HIV in developing countries?
Goemaere E; Kaninda AV; Ciaffi L; Mulemba M; t Hoen E; Pécoul B
JAMA; 2002 Feb; 287(7):841-2; author reply 842-3. PubMed ID: 11851569
[No Abstract] [Full Text] [Related]
15. World CAB meets with Gilead.
Huff B
GMHC Treat Issues; 2006; 20(4-7):6-8. PubMed ID: 17228449
[No Abstract] [Full Text] [Related]
16. Trip into the unknown.
Anderson T
Nature; 2007 Nov; 450(7169):471. PubMed ID: 18033269
[No Abstract] [Full Text] [Related]
17. New frontier of AIDS activism: international trade rules and global access to medicines. Interview by John S. James.
Sawyer E
AIDS Treat News; 1999 Apr; (No 317):1, 5-8. PubMed ID: 11366992
[TBL] [Abstract][Full Text] [Related]
18. World pharmaceutical developments.
Bale H
World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
[No Abstract] [Full Text] [Related]
19. Drug firms lose patent rights lawsuit against South Africa's government.
Baleta A
Lancet; 2001 Apr; 357(9265):1347. PubMed ID: 11343755
[No Abstract] [Full Text] [Related]
20. Do patents prevent access to drugs for HIV in developing countries?
Boelaert M; Lynen L; Van Damme W; Colebunders R
JAMA; 2002 Feb; 287(7):840-1; author reply 842-3. PubMed ID: 11851568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
